公开(公告)号：US06706512B2

公开(公告)日：2004-03-16

申请号：US10165442

申请日：2002-06-07

申请人： Andras Gruber ,  Stephen R. Hanson ,  Enrico De Cera

发明人： Andras Gruber ,  Stephen R. Hanson ,  Enrico De Cera

IPC分类号： C12N964

CPC分类号： C12N9/6464 ,  A61K38/00 ,  C12N9/6429 ,  C12Q1/40 ,  C12Y304/21005 ,  C12Y304/21069 ,  G01N33/86

摘要： The present invention relates to novel antithrombotic variants of thrombin or fragments thereof that are capable of proteolytically activating protein C, but which are substantially free of fibrinogen cleavage activity. The present invention further relates to variant polypeptidess that may be cleaved to yield active thrombin variants. The present invention also relates to methods of inhibiting thrombus formation in an animal or human subject by delivering an antithrombotic variant thrombin of the present invention to the blood of the subject. The present invention relates also to methods that use the novel variant thrombins for determining the level of protein C activation in a blood sample, or the thrombogenic potential of a patient.

摘要翻译： 本发明涉及能够蛋白水解活化蛋白C但基本上不含纤维蛋白原裂解活性的凝血酶或其片段的新型抗血栓形成变体。 本发明还涉及可被切割以产生活性凝血酶变体的变体多肽。 本发明还涉及通过将本发明的抗血栓形成变体凝血酶递送至受试者的血液来抑制动物或人受试者中血栓形成的方法。 本发明还涉及使用新型变体血栓素来测定血液样品中蛋白C活化水平或患者血栓形成潜力的方法。

公开(公告)号：US07223583B2

公开(公告)日：2007-05-29

申请号：US10699393

申请日：2003-10-31

申请人： Andras Gruber ,  Stephen R. Hanson ,  Enrico De Cera

发明人： Andras Gruber ,  Stephen R. Hanson ,  Enrico De Cera

IPC分类号： C12N9/64 ,  A61K38/48

CPC分类号： C12N9/6464 ,  A61K38/00 ,  C12N9/6429 ,  C12Q1/40 ,  C12Y304/21005 ,  C12Y304/21069 ,  G01N33/86

摘要： The present invention relates to novel antithrombotic variants of thrombin or fragments thereof that are capable of proteolytically activating protein C, but which are substantially free of fibrinogen cleavage activity. The present invention further relates to variant polypeptides that may be cleaved to yield active thrombin variants. The present invention also relates to methods of inhibiting thrombus formation in an animal or human subject by delivering an antithrombotic variant thrombin of the present invention to the blood of the subject. The present invention relates also to methods that use the novel variant thrombins for determining the level of protein C activation in a blood sample, or the thrombogenic potential of a patient.

摘要翻译： 本发明涉及能够蛋白水解活化蛋白C但基本上不含纤维蛋白原裂解活性的凝血酶或其片段的新型抗血栓形成变体。 本发明还涉及可被切割以产生活性凝血酶变体的变体多肽。 本发明还涉及通过将本发明的抗血栓形成变体凝血酶递送至受试者的血液来抑制动物或人受试者中血栓形成的方法。 本发明还涉及使用新型变体血栓素来测定血液样品中蛋白C活化水平或患者血栓形成潜力的方法。